LONDON -- Successful investors use a disciplined approach to picking stocks, and checklists can be a great way to make sure you've covered all the bases.
In this series I'm subjecting companies to scrutiny under five headings: prospects, performance, management, safety and valuation. How does�GlaxoSmithKline� (LSE: GSK ) (NYSE: GSK ) measure up?
1.�Prospects
The pharmaceutical industry is riding a demographic wave of aging populations in developed countries and increasing wealth in developing ones. However, many companies are suffering competition from generic manufacturers as patents expire.
GSK is one of the world's biggest drug makers, giving it the firepower to spend heavily on R&D, and it has a promising pipeline. Vaccines and consumer health care products (30% of sales) provide stability and the latter helps GSK's big push into emerging markets.
2.�Performance
Turnover has been gently declining in recent years, but this trend is expected to reverse as new drugs come on stream from the end of this year. Operating profit has been variable, but GSK earns gross margins above 20%.
Top Building Product Companies To Watch For 2015: The Fresh Market Inc.(TFM)
The Fresh Market, Inc. operates as a specialty grocery retailer. The company offers various perishable product categories, including meat, seafood, produce, deli, bakery, floral, sushi, and prepared foods; and non-perishable product categories, such as traditional grocery and dairy products, as well as specialty foods, which include bulk, coffee and candy, and beer and wine. As of March 20, 2012, it operated 115 stores in 21 states located in the southeast, midwest, mid-Atlantic, and northeast of United States. The company was founded in 1981 and is headquartered in Greensboro, North Carolina.
Advisors' Opinion:- [By Jayson Derrick]
The Fresh Market (NYSE: TFM) plunged 18.91 percent closing at $40.87 following the company's disappointing earnings report Thursday. The company missed on both EPS and revenues front.
- [By Brian Stoffel]
Much has been made recently about new entrants into the organic/natural food space in America. While Sprouts Farmers Market� (NASDAQ: SFM ) , The Fresh Market (NASDAQ: TFM ) , and Natural Grocers by Vitamin Cottage� (NYSE: NGVC ) attempt to use Whole Foods' blueprint, Wal-Mart (NYSE: WMT ) is teaming up with Wild Oats to offer more organic goods in its discount stores.
Top Promising Stocks For 2014: Etfs Gold Trust (SGOL)
ETFS Gold Trust (the Trust) is an investment trust. The investment objective of the Trust is for the Shares to reflect the performance of the price of gold bullion, less the expenses of the Trust�� operations. The Trust holds gold bullion and issues ETFS Physical Swiss Gold Shares (the Shares) in exchange for deposits of gold and distributes gold in connection with redemption of Baskets. The sponsor of the Trust is ETF Securities USA LLC (the Sponsor). The trustee of the Trust is The Bank of New York Mellon and the custodian is JP Morgan Chase Bank N.A. Advisors' Opinion:- [By Peter Pham]
Although the Fed doubled its bond buying last September, the top gold exchange-traded funds, or ETFs, including SPDR Gold Shares (NYSEMKT: GLD ) , iShares Gold Trust (NYSEMKT: IAU ) , and ETFS Physical Swiss Gold Shares (NYSEMKT: SGOL ) , have dropped around 25% each over the last 12 months, which speaks to gold's extreme vulnerability to QE tapering. Even the mere mention of tapering seems to send gold into a tailspin, as seen with SPDR Gold Shares, which has plunged 24% year to date and also suffered massive losses with its physical holdings. Market Vectors Gold Miners ETF (NYSEMKT: GDX ) has suffered a massive drop of 48% so far in 2013, making it one of the worst-performing ETFs this year.
Top Promising Stocks For 2014: BG Medicine Inc.(BGMD)
BG Medicine, Inc., a life sciences company, engages in the discovery, development, and commercialization of diagnostic tests based on biomarkers in the United States. Its product pipeline includes BGM Galectin-3, a diagnostic test for heart failure that measures galectin-3 levels in blood plasma or serum; AMIPredict, a multivariate biomarker blood-based test for atherothrombotic cardiovascular disease; and LipidDx, a blood-based protein assay for the management of patients with lipid disorders. The company also offers TNF alpha blockers comprising Enbrel, Remicade and Humira, which are treatments indicated for autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn?s disease. It has strategic collaborations and initiatives with pharmaceutical companies and other healthcare organizations, including Abbott Laboratories; ACS Biomarker B.V.; Humana Inc.; Merck & Co., Inc.; and Laboratory Corporation of America. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.
Advisors' Opinion:- [By Roberto Pedone]
Another stock that's starting to move within range of triggering a big breakout trade is BG Medicine (BGMD), which develops and commercializes novel cardiovascular diagnostic tests to address unmet medical needs in the U.S. This stock has been pushed lower by the sellers over the last three months, with shares down sharply by 20%.
If you take a glance at the chart for BG Medicine, you'll notice that this stock has been uptrending a bit for the last month, with shares moving higher from its low of 90 cents per share to its recent high of $1.12 a share. During that uptrend, shares of BGMD have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of BGMD within range of triggering a big breakout trade above some key near-term overhead resistance levels.
Traders should now look for long-biased trades in BGMD if it manages to break out above some near-term overhead resistance levels at $1.08 to $1.12 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.56 million shares. If that breakout gets started soon, then BGMD will set up to re-fill some of its previous gap-down-day zone from May that started near $1.30 a share. Any high-volume move above $1.30 will then give BGMD a chance to tag its next major overhead resistance levels at $1.50 to around $1.70 a share.
Traders can look to buy BGMD off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at 96 cents to 90 cents per share. One can also buy BGMD off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By James E. Brumley]
What do BG Medicine, Inc. (NASDAQ:BGMD) and Pentair, Ltd. (NYSE:PNR) have in common? Most investors would say absolutely nothing. BGMD is a small cap medical diagnostics company, while PNR is a large cap industrial equipment manufacturer. Those are worlds that simply never collide. The directions each stock has been traveling in over the past few months have even been polar opposites.
Top Promising Stocks For 2014: Allegiant Travel Co (ALGT)
Allegiant Travel Company, incorporated on April 4, 2006, is a leisure travel company focused on providing travel services and products to residents of small, underserved cities in the United States. The Company operates a passenger airline marketed primarily to leisure travelers in small cities, allowing it to sell air transportation both on a stand-alone basis and bundled with the sale of air-related and third party services and products. In addition, it provides air transportation under fixed fee flying arrangements. The Company provides scheduled air transportation on limited frequency nonstop flights between small city markets and leisure destinations. As of February 1, 2013, its operating fleet consisted of 58 MD-80 aircraft and six Boeing 757-200 aircraft providing service on 191 routes to 85 cities including 13 leisure destinations and 72 small cities and including cities served seasonally. In January 2012, the Company took ownership of two MD-80 aircraft. In October 2012, the Company announced the formation of Allegiant Systems, a joint venture with AvIntel and Lixar IT.
The Company provides unbundled air-related services and products in conjunction with air transportation for an additional cost to customers. These optional air-related services and products include use of its Website for purchases, use of its call center for purchases, advance seat assignment, baggage fees, priority boarding, its own travel protection product, change fees, food and beverage purchases on board and other air-related services. The Company offers third party travel products, such as hotel rooms, ground transportation (rental cars and hotel shuttle products) and attractions (show tickets) bundled with the purchase of its air transportation.
The Company provides air transportation through fixed fee agreements and charter service on a seasonal and ad-hoc basis for other customers. As of February 1, 2013, its operating aircraft consisted of 58 MD-80 aircraft and six Boeing 757-200 aircraft. D! uring the year ended December 31, 2012, the Company has entered into purchase agreements to acquire seven Airbus A320 aircraft and operating lease agreements for an additional nine Airbus A319 aircraft.
The Company competes with AirTran, Frontier, Spirit, Southwest, US Airways, Alaska Airlines, Horizon Air, Delta, Xtra, United and American.
Advisors' Opinion:- [By Sean Williams]
Another key point to Southwest's success has been its constant focus on giving the customer top value among domestic carriers. You'll certainly find a cheaper upfront ticket price if you look around for domestic flights from a small regional carrier like Allegiant Travel (NASDAQ: ALGT ) or Spirit Airlines (NASDAQ: SAVE ) . Then again, Southwest doesn't charge for the first two checked bags, whereas Allegiant and Spirit charge for both each checked bag as well as carry-on bags! Southwest's keep-it-simple approach and easy-to-understand pricing have been instrumental in winning over passengers.
- [By Adam Levine-Weinberg]
Rise of the carry-on-bag fee
In April 2010, ultra-low-cost carrier Spirit Airlines (NASDAQ: SAVE ) became the first airline in the U.S. (and possibly the world) to introduce a fee for carry-on baggage. Spirit's management decided that adding a carry-on baggage fee would allow them to reduce base airfares, stimulating demand, while improving efficiency by discouraging travelers from bringing large carry-on bags. Two years later, Spirit finally got some company as fellow ULCC Allegiant Travel (NASDAQ: ALGT ) instituted its own carry-on-bag charge.
Top Promising Stocks For 2014: Anacor Pharmaceuticals Inc. (ANAC)
Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company�s lead product candidates include tavaborole, an antifungal product candidate that is in Phase III clinical development for the treatment of onychomycosis; and AN2728, an anti-inflammatory product candidate, which completed Phase II clinical trials for the treatment of atopic dermatitis and psoriasis. It also develops AN5568, a Phase I human clinical trial product targeting human African trypanosomiasis; and other compounds to treat animal health indications. The company�s clinical pipeline also includes AN2718, a topical antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin; AN2898, a topical anti-inflammatory product candidate that completed the Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis; and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. It has research, development, and collaboration agreements with GlaxoSmithKline LLC, Eli Lilly and Company, Medicis Pharmaceutical Corporation, and Medicines for Malaria Ventures. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in October 2002. Anacor Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Palo Alto, California.
Advisors' Opinion:- [By Roberto Pedone]
Anacor Pharmaceuticals (ANAC), a biopharmaceutical company, focuses on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. This stock closed up 6.6% to $16.90 in Monday's trading session.
Monday's Volume: 2.22 million
Three-Month Average Volume: 425,667
Volume % Change: 412%From a technical perspective, ANAC gapped sharply higher here back above both its 50-day moving average of $15.97 and its 200-day moving average of $16.50 with monster upside volume. This stock recently formed a double bottom chart pattern at $14.95 to $15.11. Since tagging that bottom, shares of ANAC have started to rip higher and move within range of triggering a big breakout trade. That trade will hit if ANAC manages to take out Monday's intraday high of $17.03 to $17.62 and then once it clears more near-term overhead resistance at $18.73 with high volume.
Traders should now look for long-biased trades in ANAC as long as it's trending above Monday's intraday low of $16.15 and then once it sustains a move or close above those breakout levels with volume that hits near or above 425,667 shares. If that breakout kicks off soon, then ANAC will set up to re-test or possibly take out its next major overhead resistance levels at $21.27 to $23.07.
- [By Lauren Pollock]
Valeant Pharmaceuticals International Inc.(VRX.T) will pay $142.5 million to Anacor Pharmaceuticals Inc.(ANAC) to resolve all outstanding disputes between the two companies. The settlement resolves litigation over alleged breaches of contract involving Valeant units Dow Pharmaceuticals Sciences Inc. and Medicis Pharmaceutical Corp.
Top Promising Stocks For 2014: Carnival Plc ADS (CUK)
Carnival plc operates as a cruise company. It operates in North America Cruise Brands, EAA Cruise Brands, and Tour and Other segments. The company offers cruises under the brand names of Carnival Cruise Lines, Holland America Line, Princess Cruises, and Seabourn in North America; and AIDA Cruises, Costa Cruises, Cunard, Ibero Cruises, P&O Cruises (UK), and P&O Cruises (Australia) in Europe, Australia, and Asia. It also owns Holland America Princess Alaska Tours, a tour operator in Alaska and the Canadian Yukon, which owns and operates 12 hotels or lodges, 300 motor coaches, and 20 domed rail cars. The company sells its cruises through travel agents, including wholesalers, general sales agents, and tour operators. Carnival plc was founded in 1850 and is headquartered in London, the United Kingdom.
Advisors' Opinion:- [By Peter Graham]
The Q3 2014 earnings report for cruise ship stock Carnival Corporation (NYSE: CCL), which also has a listing as Carnival plc (NYSE: CUK) and is a peer of�Royal Caribbean Cruises Ltd (NYSE: RCL) and Norwegian Cruise Line Holdings Ltd (NASDAQ: NCLH), is scheduled to report earnings before the market opens on Tuesday (September 23rd). Aside from the Carnival Corporation earnings report, it should be said that Royal Caribbean Cruises Ltd reported Q2 2014 earnings on July 24th (profit rose fivefold on higher European demand) and Norwegian Cruise Line Holdings Ltd reported Q2 2014 earnings on July 29th (investments in new ships and fleet modernization helped earnings that beat expectations). However and the last time around when Carnival Corporation reported earnings, year over year comparisons may have been misleading because�of an embarrassing February 2013 incident when a�fire on the Carnival Triumph left the ship without power in the Gulf of Mexico and�passengers stranded aboard the stalled ship for four days until it was pulled into port by several tugboats.
No comments:
Post a Comment